title: Alopecia areata universalis complicating daclizumab therapy for uveitis.
abstract: Alopecia areata (AA) is a complication of biologic therapy with several anti-tumor necrosis factor (TNF) inhibitors and efalizumab for the treatment of various autoimmune diseases. We report the case of a 51-year-old woman who developed AA universalis while undergoing treatment with daclizumab, an immunosuppressive biologic therapy, administered for treatment of inflammatory ocular disease. Although immunomodulatory agents that function by interfering with T helper cell stimulation are expected to impede autoimmune-related processes, we believe that daclizumab may be causally related to the development of AA.
authors.forename: Adam K
authors.initials: AK
authors.lastname: Rosenstein
authors.forename: Brian C
authors.initials: BC
authors.lastname: Machler
authors.affiliation: Institute for Rheumatic and Autoimmune Diseases, Overlook Medical Center, 33 Overlook Rd, Summit, NJ, USA. elliot.rosenstein@atlantichealth.org.
authors.forename: Elliot D
authors.initials: ED
authors.lastname: Rosenstein
mesh_terms: D000506:Alopecia Areata / Q000139:chemically induced* / Q000473:pathology; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000077561:Daclizumab; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008875:Middle Aged; D014605:Uveitis / Q000188:drug therapy*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab